全球生技藥品安全檢測市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計到 2034 年，生技藥品安全檢測市場規模將達到 195.5 億美元，高於 2025 年的 60.8 億美元，預計從 2026 年到 2034 年的複合年成長率將達到 13.86%。

由於生物製藥、疫苗和生物相似藥的持續研發，全球生技藥品安全檢測市場正經歷快速成長。安全檢測對於確保這些產品在上市前符合嚴格的監管標準至關重要。慢性病盛行率的上升以及對先進治療方法需求的不斷成長，顯著增加了對生技藥品的需求，進而推動了整個製藥和生物技術行業對安全檢測解決方案的需求。

主要促進因素包括嚴格的監管要求、研發活動的活性化以及臨床試驗數量的上升。向個人化醫療和標靶治療的轉變進一步提升了生物製藥安全性測試的重要性。此外，包括自動化和快速檢測方法在內的檢測技術的進步提高了效率和準確性，使檢測過程更加快速可靠。

預計未來市場將持續成長，這主要得益於生物技術和法規結構的不斷進步。人工智慧和數位技術的融合將提升檢測能力並縮短檢測週期。新興市場製藥業的擴張將創造新的成長機會。隨著生物製藥在現代治療方法中繼續佔據主導地位，對安全性檢測的需求將保持強勁且至關重要。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球生技藥品安全偵測市場：依產品與服務分類

• 市場分析、洞察與預測
• 消耗品
• 裝置
• 服務
• 試劑和試劑盒

第5章 全球生技藥品安全偵測市場：依應用領域分類

• 市場分析、洞察與預測
• 疫苗和治療
• 血液及血液製品
• 基因治療
• 組織及其衍生產品
• 幹細胞

第6章 全球生技藥品安全檢測市場：依檢測類型分類

• 市場分析、洞察與預測
• 內毒素試驗
• 無菌測試
• 黴漿菌檢測
• 微生物附著量測試
• 殘留宿主細胞蛋白質和DNA檢測
• 病毒安全測試
• 外來性因子檢測
• 其他測試類型

第7章 全球生技藥品安全偵測市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • BioMerieux SA
  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Lonza Group Ltd
  • Merck KGaA
  • Samsung Biologics
  • Sartorius AG
  • SGS Societe Generale De Surveillance SA
  • Thermo Fisher Scientific Inc

The Biologics Safety Testing Market size is expected to reach USD 19.55 Billion in 2034 from USD 6.08 Billion (2025) growing at a CAGR of 13.86% during 2026-2034.

The global biologics safety testing market is experiencing rapid growth due to the increasing development of biologic drugs, vaccines, and biosimilars. Safety testing is essential to ensure that these products meet strict regulatory standards before reaching the market. The rising prevalence of chronic diseases and the growing demand for advanced therapies have significantly increased the need for biologics, thereby driving demand for safety testing solutions across pharmaceutical and biotechnology industries.

Key drivers include stringent regulatory requirements, increasing research and development activities, and the growing number of clinical trials. The shift toward personalized medicine and targeted therapies has further boosted the importance of biologics safety testing. Additionally, advancements in testing technologies, including automation and rapid detection methods, are improving efficiency and accuracy, making testing processes faster and more reliable.

In the future, the market is expected to grow with continued advancements in biotechnology and regulatory frameworks. The integration of artificial intelligence and digital technologies will enhance testing capabilities and reduce turnaround times. Expanding pharmaceutical industries in emerging markets will create new growth opportunities. As biologics continue to dominate modern therapeutics, the demand for safety testing will remain strong and essential.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product and Services

• Consumables
• Instruments
• Services
• Reagents and kits

By Application

• Vaccine and therapeutics
• Blood and blood-based products
• Gene therapy
• Tissue and tissue-based products
• Stem cells

By Test Type

• Endotoxin tests
• Sterility tests
• Mycoplasma tests
• Bioburden tests
• Residual host-cell proteins and DNA detection tests
• Virus safety tests
• Adventitious agent detection tests
• Other test types

COMPANIES PROFILED

• bioMrieux SA, Charles River Laboratories International Inc, Eurofins Scientific SE, F HoffmannLa Roche Ltd, Lonza Group Ltd, Merck KGaA, Samsung Biologics, Sartorius AG, SGS Socit Gnrale de Surveillance SA, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOLOGICS SAFETY TESTING MARKET: BY PRODUCT AND SERVICES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product And Services
• 4.2. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Reagents and kits Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOLOGICS SAFETY TESTING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Vaccine and therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Blood and blood-based products Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Gene therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Tissue and tissue-based products Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Stem cells Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOLOGICS SAFETY TESTING MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Test Type
• 6.2. Endotoxin tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Sterility tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Mycoplasma tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Bioburden tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Residual host-cell proteins and DNA detection tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Virus safety tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Adventitious agent detection tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Other test types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOLOGICS SAFETY TESTING MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product And Services
  • 7.2.2 By Application
  • 7.2.3 By Test Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product And Services
  • 7.3.2 By Application
  • 7.3.3 By Test Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product And Services
  • 7.4.2 By Application
  • 7.4.3 By Test Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product And Services
  • 7.5.2 By Application
  • 7.5.3 By Test Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product And Services
  • 7.6.2 By Application
  • 7.6.3 By Test Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL BIOLOGICS SAFETY TESTING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 BioMerieux S.A
  • 9.2.2 Charles River Laboratories International Inc
  • 9.2.3 Eurofins Scientific SE
  • 9.2.4 F. Hoffmann-La Roche Ltd
  • 9.2.5 Lonza Group Ltd
  • 9.2.6 Merck KGaA
  • 9.2.7 Samsung Biologics
  • 9.2.8 Sartorius AG
  • 9.2.9 SGS Societe Generale De Surveillance SA
  • 9.2.10 Thermo Fisher Scientific Inc